Dual acting therapeutic proteins for intraocular use
Article
Collins, M., Awwad, S., Ibeanu, N., Khaw, P. T., Guiliano, D., Brocchini, S. and Khalili, H. 2020. Dual acting therapeutic proteins for intraocular use. Drug Discovery Today. 26 (1), pp. 44-55. https://doi.org/10.1016/j.drudis.2020.10.025
Authors | Collins, M., Awwad, S., Ibeanu, N., Khaw, P. T., Guiliano, D., Brocchini, S. and Khalili, H. |
---|---|
Abstract | Antibody-based medicines that target vascular endothelial growth factor (VEGF) are administered by intravitreal injection to treat chronic neovascular retinal diseases. Much ongoing effort is focused on enhancing therapeutic outcome of these medicines. One strategy is the use of dual acting drugs (e.g. bispecific antibodies) to simultaneously bind to more than one intraocular biological target. A dual acting molecule targeting components within the vitreal cavity could also potentially extend vitreous residence time. In this review, the applications of bispecific antibodies within the eye are described with consideration to potential targets, applications and suitable bispecific formats. |
Journal | Drug Discovery Today |
Journal citation | 26 (1), pp. 44-55 |
ISSN | 1359-6446 |
Year | 2020 |
Publisher | Elsevier |
Accepted author manuscript | License File Access Level Anyone |
Digital Object Identifier (DOI) | https://doi.org/10.1016/j.drudis.2020.10.025 |
Publication dates | |
Online | 01 Nov 2020 |
Publication process dates | |
Accepted | 26 Oct 2020 |
Deposited | 28 Oct 2020 |
Funder | National Institute of Health Research Biomedical Research Centre |
Copyright holder | © 2020 Elsevier |
Permalink -
https://repository.uel.ac.uk/item/88q0x
Download files
Accepted author manuscript
Revised DRUDIS-D-20-00182_to submit For Roar.pdf | ||
License: CC BY-NC-ND 4.0 | ||
File access level: Anyone |
246
total views185
total downloads1
views this month3
downloads this month